NovaBridge Biosciences
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBP research report →
Companywww.i-mabbiopharma.com
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor.
- CEO
- Xi-Yong Fu
- IPO
- 2020
- Employees
- 32
- HQ
- Rockville, MD, US
Price Chart
Valuation
- Market Cap
- $193.65M
- P/E
- -4.24
- P/S
- 0.00
- P/B
- 2.55
- EV/EBITDA
- -5.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -3.50%
- ROIC
- -94.82%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-6,614,616 · 95.92%
- EPS
- $-0.16 · 96.46%
- Op Income
- $-13,476,696
- FCF YoY
- 60.92%
Performance & Tape
- 52W High
- $6.79
- 52W Low
- $0.90
- 50D MA
- $2.46
- 200D MA
- $3.68
- Beta
- 1.56
- Avg Volume
- 1.01M
Get TickerSpark's AI analysis on NBP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Cao Sean Wuxiong | sell | 21,399 |
| Apr 24, 26 | Hagler Mark Arnold | buy | 230,000 |
| Apr 17, 26 | Hagler Mark Arnold | other | 0 |
| Mar 18, 26 | Xu Cong Claire | other | 0 |
| Mar 18, 26 | Yang Conor Chia-hung | other | 114,093 |
| Mar 18, 26 | Yang Conor Chia-hung | other | 34,530 |
| Mar 18, 26 | Chu Denny Hsueh Wen | other | 0 |
| Mar 18, 26 | Dennis Phillip Andrew | other | 0 |
| Mar 18, 26 | Dennis Phillip Andrew | other | 494,510 |
| Mar 18, 26 | Dennis Phillip Andrew | other | 186,300 |
Our NBP Coverage
We haven't published any research on NBP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NBP Report →